Who Supplies Pemetrexed to India from NETHERLANDS

Importing finished pharmaceutical formulations containing Pemetrexed into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product type. The registration process includes providing detailed product information, manufacturing details, and proof of compliance with Good Manufacturing Practices (GMP). The timeline for import drug registration can vary but typically ranges from 6 to 12 months. For formulations under HS Code 30049049, specific requirements include stability data (preferably ICH Zone IV), a Certificate of Pharmaceutical Product (CoPP), and a Free Sale Certificate from the country of origin.

Imported pharmaceutical formulations containing Pemetrexed must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, should be provided, adhering to ICH guidelines for Zone IV conditions. Upon arrival, customs drug inspectors perform port inspections to verify product authenticity and quality. If a batch fails quality testing, it may be rejected, leading to potential financial losses and reputational damage for the importer.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting pharmaceutical imports. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and the Netherlands have facilitated smoother trade processes, including mutual recognition of GMP certifications, thereby reducing import lead times. These developments aim to balance the promotion of domestic industry with the need for high-quality imported formulations.

India imports finished Pemetrexed formulations primarily due to the demand for patented and branded products not yet manufactured domestically. Specific dosage forms, such as injectable formulations, are often sourced from international markets to meet therapeutic needs. While domestic manufacturers like Shilpa Medicare Ltd. produce Pemetrexed APIs and some formulations, the complexity and cost of developing certain finished dosage forms lead to continued reliance on imports. The Indian market for Pemetrexed formulations is substantial, with imports valued at approximately $28.8 million across 138 exporters to 92 countries.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049049 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% is applied, calculated on the BCD. The Integrated Goods and Services Tax (IGST) rate varies based on the product's classification and applicable exemptions. There are no anti-dumping duties or additional cess applicable to this product category. Exemptions may apply under specific Free Trade Agreements (FTAs) or government notifications, potentially reducing the total landed duty percentage.

India sources finished Pemetrexed formulations from the Netherlands due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and established trade relations. The Netherlands offers competitive advantages, including patented formulations and specialized dosage forms not readily available from other suppliers. While countries like China, Germany, and the United States also supply Pemetrexed formulations, the Netherlands' consistent quality and reliability make it a preferred source. The Netherlands holds a significant share in India's Pemetrexed import market, contributing to the overall import value of $28.8 million.

India imports finished Pemetrexed formulations from the Netherlands due to the country's advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. The Netherlands' established trade relations and consistent product quality further enhance its appeal as a sourcing destination.

Compared to other origins like China, Germany, and the United States, the Netherlands offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While other countries may offer lower prices, the Netherlands' commitment to quality and established trade relationships make it a preferred source for finished Pemetrexed formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring geopolitical developments and maintaining flexibility in supply chain operations are also crucial.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.
5. 5Contractual Agreements: Establish clear contracts outlining quality standards, delivery schedules, and penalties for non-compliance.

1. 1DGFT Importer Exporter Code (IEC): Obtain a valid IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40 or 41 for product registration with CDSCO.
3. 3Drug Import License: Apply for an import license under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (N